Abstract

Epidermal growth factor (EGF) and estradiol (E2) are important mitogens in breast epithelial cells, and expression of epidermal growth factor receptor (EGFR) and estrogen receptor (ER) is often inversely correlated in human breast cancer cells. Stable transfection of ER-negative cells with ER cDNA is not sufficient to restore E2-mediated growth stimulation, on the contrary, E2 often inhibits growth of ER-transfected cell lines. In this study we used the ER-transfected human breast epithelial cell lines HMT-3522F9, growth inhibited by E2 in the presence of EGF, and HMT-3522F9/S3B, growth stimulated by E2 in the absence of EGF. In S3B cells, no active MAP kinase could be detected in response to E2, suggesting that signalling through the MAP kinase is not the major pathway in the E2-mediated growth stimulation. Interestingly, a decreased level of active MAP kinase was observed in HMT-3522F9 cells in response to E2, indicating that in these cells cross-talk between the ER and the MAP kinase signalling pathway could be due to the E2-mediated growth inhibition. Moreover, we found that EGF-induced signalling also could be reduced by E2 in S3B cells, suggesting a general mechanism of action by E2 in cells concomitantly expressing ER and EGFR.

Highlights

  • Background and purposeAkt-1 is a serine/threonineprotein kinase that regulates growth factor-dependent cell proliferation and survival

  • After the analysis of the HRAS1 MVR sequences and the length polymorphism typing in the healthy control population and the affected patients, we have observed that 20% of breast cancer patients had at least one rare HRAS1 allele compared to 6.42% of HRAS1 alleles in the control population (χ2, P = 0.0037)

  • In our recent report [1] a high frequency (33%) of germline BRCA2 mutations was detected among Hungarian male breast cancer cases without family history

Read more

Summary

Introduction

Akt-1 is a serine/threonineprotein kinase that regulates growth factor-dependent cell proliferation and survival. Activated-Akt-1 causes Bcl-2 release from the BAD:Bcl-2 inactive complex. Bcl is able to prevent apoptosis, as a downstream effector of Akt-1, and can delay cell-cycle progression. Akt-1 is over-expressed in breast cancer cell lines and tumours, while Bcl-2 has been related with tumour survival and drug resistance in vitro and to an ER+/well differentiated sub-group of tumours, in vivo. Since endocrine treatment effectiveness could be due to activation of the apoptotic program, we wanted to investigate the expression and relationship between these factors as well as other variables (C-erbB-2, ER, and S-phase)

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.